Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 24;66(2):129-136.
doi: 10.1093/jrr/rrae099.

Systemic inflammation response index predicts overall survival in patients undergoing stereotactic radiosurgery for brain metastasis from non-small cell lung cancer

Ryosuke Matsuda  1 , Tetsuro Tamamoto  2   3 , Nobuyoshi Inooka  2 , Shigeto Hontsu  4 , Akihiro Doi  5 , Ryosuke Maeoka  1 , Tsutomu Nakazawa  1 , Takayuki Morimoto  1 , Kaori Yamaki  2 , Sachiko Miura  2 , Yudai Morisaki  1 , Shohei Yokoyama  1 , Masashi Kotsugi  1 , Yasuhiro Takeshima  1 , Fumiaki Isohashi  2 , Ichiro Nakagawa  1
Affiliations

Systemic inflammation response index predicts overall survival in patients undergoing stereotactic radiosurgery for brain metastasis from non-small cell lung cancer

Ryosuke Matsuda et al. J Radiat Res. .

Abstract

This study aimed to evaluate the prognostic value of pre-treatment blood cell counts in patients with brain metastasis (BM) from non-small cell lung cancer (NSCLC) who were treated using linear accelerator (linac)-based stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) with a micro-multileaf collimator. Between January 2011 and November 2022, 271 consecutive patients underwent linac-based SRS/fSRT for BM from NSCLC. Thirty patients with insufficient blood test data during this period were excluded from this analysis. Thirty-five patients with steroid intake at the time point of the blood test and 18 patients with higher C-reactive protein were excluded. Thus, 188 patients were eventually enrolled in this study. The median follow-up period after SRS/fSRT was 21 months (range: 0-121 months), and the median survival time after SRS/fSRT was 19 months. Neutrophil-lymphocyte ratio ≥ 1.90, lymphocyte-monocyte ratio ≤ 1.67 and systemic inflammation response index (SIRI) ≥ 2.95 were unfavorable predictors of prognosis for patients who underwent SRS/fSRT for BM from NSCLC. Cox proportional-hazard multivariate analysis revealed that the SIRI was independent prognostic factors for increased risk of death. Thus, simple, less expensive, and routinely performed pre-treatment blood cell count measurements such as SIRI can predict the overall survival of patients treated with SRS/fSRT for BM from NSCLC.

Keywords: brain metastasis; neutrophil–lymphocyte ratio; non-small cell lung cancer; systemic immune-inflammation index; systemic inflammation response index.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Post-radiosurgery overall survival (OS) of the patients with brain metastasis estimated using the Kaplan–Meier method considering each parameter. (A) OS in the entire cohort, (B) neutrophil–lymphocyte ratio (NLR; black line: NLR < 1.90; red line, NLR ≥ 1.90), (C) platelet–lymphocyte ratio (PLR; black line: PLR < 202.2; red line: PLR ≥ 202.2), (D) lymphocyte–monocyte ratio (LMR; black line: LMR < 1.67; red line: LMR ≥ 1.67), (E) systemic immune-inflammation index (SII; black line: SII < 1095; red line: SII ≥ 1095), (F) systemic inflammation response index (SIRI; black line: SIRI <2.95; red line: SIRI ≥2.95).
Figure 2
Figure 2
Freedom of distant failure of the patients with brain metastasis from NSCLC who underwent SRS/fSRT estimated using the Kaplan–Meier method (A) and freedom of local failure of the patients estimated using competing risk survival analysis (B).
See this image and copyright information in PMC

References

    1. The Japanese Neurosurgical Society. Brain Tumor Registry of Japan (2005–2008) . Neurol med Chir (Tokyo) 2017;57:9–102. 10.2176/nmc.sup.2017-0001. - DOI - PMC - PubMed
    1. Matsuda R, Tamamoto T, Sugimoto T et al. Linac-based fractionated stereotactic radiotherapy with a micro-multileaf collimator for large brain metastasis unsuitable for surgical resection. J Radiat Res 2020;61:546–53. 10.1093/jrr/rraa038. - DOI - PMC - PubMed
    1. Sugimoto T, Matsuda R, Tamamoto T et al. Linac-based fractionated stereotactic radiotherapy with a micro-multileaf collimator for brainstem metastasis. World Neurosurg 2019;132:e680–e6. 10.1016/j.wneu.2019.08.049. - DOI - PubMed
    1. Wolf A, Kvint S, Chachoua A et al. Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. J Neurosurg 2018;128:23–31. 10.3171/2016.10.JNS161036. - DOI - PubMed
    1. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745–51. 10.1016/S0360-3016(96)00619-0. - DOI - PubMed